Clinton unveils deal to cut malaria drug prices

Font Size

Print

Feedback

Email

Discuss

Related Articles

US House of Rep to probe Ranbaxy issueClinton unveils deal to cut malaria drug pricesClinton unveils deal to cut malaria drug pricesFDA under Congress scanner over Ranbaxy issue

New York, July 18: : be able to shield patients from costs like Novartis has.

"With rapidly but unevenly growing demand -- and the prospect of a potential global ACT subsidy that could accelerate this growth dramatically -- the risk of volatility in the future remains high," the Clinton Foundation said.

International organizations and governments are considering a multimillion-dollar global subsidy plan for the ACT drugs.

The foundation said the agreements will help to mitigate risk so new suppliers can enter the market and current suppliers like Cipla and IPCA can expand their manufacturing.

The Clinton Foundation said that currently about 100 million doses of ACT drugs are distributed a year. It has forecast that demand for ACT drugs will at least double over the coming four years and could grow to more than 400 million doses annually if a global subsidy plan is agreed.